Research Article

Bifidobacterium animalis ssp. lactis 420 Protects against Indomethacin-Induced Gastric Permeability in Rats

Table 5

Effect of Bifidobacterium lactis 420 cell-free extract and lactic acid against indomethacin-induced side effects.

GroupaQuantities of permeability probesb (mg/sample ± SD)TDAc (mm2 ± SD)
SucroseLactulose : mannitol

Control21.63 ± 7.231.36 ± 0.28d, e0.70 ± 2.44f, g, h
NSAID28.58 ± 11.382.04 ± 0.45d6.28 ± 6.85f
Live cells19.71 ± 10.611.83 ± 0.53e2.84 ± 3.12g
Cell free extract22.48 ± 14.411.60 ± 0.511.88 ± 2.41
Lactic acid24.90 ± 12.241.76 ± 0.387.48 ± 9.21h

aThe treatment groups were a control group, an indomethacin-challenged group (NSAID), and groups supplemented daily with 1010 colony forming units of Bifidobacterium lactis B420 (live cells), B. lactis 420 cell-free extract (cell-free extract), or lactic acid for seven days prior to indomethacin challenge.
bSucrose measures gastric permeability and the Lactulose : mannitol-ratio reflects small-intestinal permeability.
cTDA stands for total damaged area.
d-hSignificant (ANOVA; P < 0.05) differences between treatment groups are denoted pair wise by superscript letters.